Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ESRRA | P11474 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815388 | 0.92 | ALDH1A1 (0.55) | RORCSMN1; SMN2L3MBTL1HTTPOLB | |
| SCHEMBL9756597 | 0.87 | RORC (0.56) | RORCSMN1; SMN2L3MBTL1POLBALDH1A1 | |
| SCHEMBL6815392 | 0.85 | RORC (0.41) | RORCSMN1; SMN2L3MBTL1HTTPOLB | |
| SCHEMBL10619104 | 0.85 | RORC (0.62) | RORCSMN1; SMN2L3MBTL1POLBALDH1A1 | |
| SCHEMBL27916473 | 0.82 | RORC (0.55) | RORCSMN1; SMN2L3MBTL1POLBALDH1A1 | |
| SCHEMBL11622425 | 0.82 | RORC (0.55) | RORCSMN1; SMN2L3MBTL1POLBALDH1A1 | |
| SCHEMBL7157865 | 0.80 | CYP17A1 (0.45) | SMN1; SMN2POLBALDH1A1IDO1MEN1 | |
| SCHEMBL27820437 | 0.79 | RORC (0.56) | RORCSMN1; SMN2L3MBTL1POLBALDH1A1 | |
| SCHEMBL6571935 | 0.79 | MAPT (0.45) | SMN1; SMN2L3MBTL1HTTPOLBALDH1A1 | |
| SCHEMBL9773576 | 0.79 | POLB (0.50) | SMN1; SMN2L3MBTL1HTTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2493862-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | IDO1, IDO2, INMT | RORC 729/4885SMN1; SMN2 4752/4885L3MBTL1 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.